Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06406452 · ClinicalTrials.gov registry record · NA
Bioresorbable Airway Splint Pivotal Clinical Trial
A NA study of Tracheobronchomalacia, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06406452 is a NA study of Tracheobronchomalacia that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06406452, a NA study of Tracheobronchomalacia, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn if a three-dimensional (3D) printed airway splint device made to hold open a collapsing airway is a safe and effective treatment of Tracheobronchomalacia (TBM) in children. The airway splint is bioresorbable, meaning the child's body will absorb the splint over about five years.
Conditions Studied
Interventions
- DEVICE Bioresorbable Tracheobronchial Splint
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2034-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06406452
The ClinicalTrials.gov registry entry for NCT06406452 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tracheobronchomalacia appearing as the primary indexed condition, and to 1 intervention - of which Bioresorbable Tracheobronchial Splint is the first listed.
NCT06406452 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06406452 about?
NCT06406452 is a clinical study titled "Bioresorbable Airway Splint Pivotal Clinical Trial". The purpose of this study is to learn if a three-dimensional (3D) printed airway splint device made to hold open a collapsing airway is a safe and effective treatment of Tracheobronchomalacia (TBM) in children. The airway splint is bioresorbable, meaning the child's body will absorb the splint over...
What is the current status of trial NCT06406452?
This trial is currently recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2025-01-07. Estimated completion is 2034-03.
What conditions does trial NCT06406452 study?
This clinical trial studies the following conditions: Tracheobronchomalacia.
What interventions are being tested in trial NCT06406452?
The interventions under investigation include: Bioresorbable Tracheobronchial Splint (DEVICE).
Who is sponsoring clinical trial NCT06406452?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06406452 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tracheobronchomalacia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.